$184,786,391

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

to MAPP BIOPHARMACEUTICAL, INC.

biotechactive

ACTION DATE2026-05-12·SOURCEUSASPENDING·SOURCE IDCONT_AWD_75A50122C00061_7505_-NONE-_-NONE-

Award description

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Procurement of therapeutic treatments for Ebola, Sudan, and Marburg viruses to support public health preparedness.

Sub-sectors

vaccine-developmenttherapeutic-procurementpandemic-preparedness

Why this matters

Secures critical medical countermeasures against high-mortality viral threats; demonstrates U.S. commitment to biosecurity and outbreak response capacity.

Supply-chain signal

Large-scale procurement signals demand for specialized biopharmaceutical manufacturing and cold-chain logistics for rare-disease therapeutics.

U.S.–China competition angle

Reflects U.S. investment in biodefense independence; contrasts with potential reliance on foreign suppliers for pandemic-critical therapeutics.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002236.

Period of performance

Start

2022-09-30

End

2030-09-30

Status

activein 1598 days

Recipient

MAPP BIOPHARMACEUTICAL, INC.

UEI M9V9QTHR1H28

View full profile →

Other awards from this recipient

See all →

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00061_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.